Guardant Health’s Post

Labcorp's most recent research, presented at the 2024 SGO Annual Meeting, highlights the crucial role of biomarker testing in guiding personalized treatments for epithelial ovarian cancer. Genomic profiling is transforming patient care, ensuring better patient outcomes through tailored therapies #precisionmedicine #cancerdiagnostics #biotouch https://hubs.li/Q02pYm3c0

#ScientificSaturday 🔬Gefitinib ― is a targeted cancer therapy drug, specifically a tyrosine kinase inhibitor, used primarily to treat non-small cell lung cancer (NSCLC) with certain mutations in the epidermal growth factor receptor (EGFR) gene. By inhibiting EGFR, gefitinib helps slow or stop the growth of cancer cells that overexpress this protein. It is administered orally and is most effective in patients whose tumors have specific EGFR mutations, determined through genetic testing. While gefitinib has improved treatment outcomes for some patients, it can also cause side effects such as skin reactions and diarrhea, and its effectiveness may diminish over time due to drug resistance. ❗This study explores the mechanisms behind gefitinib resistance in lung adenocarcinoma (LUAD) patients with EGFR mutations, focusing on the role of ferroptosis, a form of programmed cell death. The researchers discovered that gefitinib resistance in EGFR-mutated LUAD cells is partly due to the inhibition of ferroptosis, with the aldo-keto reductase family 1 member C1 (AKR1C1) identified as significantly upregulated in resistant cell strains, correlating with poorer patient outcomes. Further, they revealed that AKR1C1 upregulation is mediated by the decreased expression of miR-338-3p and the involvement of the long non-coding RNA NEAT1_1, which sponges miR-338-3p, neutralizing its suppression of AKR1C1. To read what else this study uncovered, click the link below. BioPharma Services Inc. has previously completed multiple clinical trials on Gefitinib. Trust our world-class Pharmacokinetic team with your next #Phase1, BA/BE or Human Abuse Liability (#HAL) drug development project. Read the full blog here: 👇 https://hubs.li/Q02qqyMT0 Discover our Services: 👇 https://hubs.li/Q02qqDKs0 #clinicalresearch #biopharma #drugdevelopment #drugresearch #cro #clinicaltrials

The level of evidence continues to build.

Interesting paper in Cancer Cell: Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization https://lnkd.in/eswEPDcc Monocyte-derived tumor-associated macrophages (Mo-TAMs) intensively infiltrate diffuse gliomas with remarkable heterogeneity. Using single-cell transcriptomics, we chart a spatially resolved transcriptional landscape of Mo-TAMs across 51 patients with isocitrate dehydrogenase (IDH)-wild-type glioblastomas or IDH-mutant gliomas. We characterize a Mo-TAM subset that is localized to the peri-necrotic niche and skewed by hypoxic niche cues to acquire a hypoxia response signature. Hypoxia-TAM destabilizes endothelial adherens junctions by activating adrenomedullin paracrine signaling, thereby stimulating a hyperpermeable neovasculature that hampers drug delivery in glioblastoma xenografts. Accordingly, genetic ablation or pharmacological blockade of adrenomedullin produced by Hypoxia-TAM restores vascular integrity, improves intratumoral concentration of the anti-tumor agent dabrafenib, and achieves combinatorial therapeutic benefits. Increased proportion of Hypoxia-TAM or adrenomedullin expression is predictive of tumor vessel hyperpermeability and a worse prognosis of glioblastoma. Our findings highlight Mo-TAM diversity and spatial niche-steered Mo-TAM reprogramming in diffuse gliomas and indicate potential therapeutics targeting Hypoxia-TAM to normalize tumor vasculature.

As colorectal cancer (CRC) continues to challenge us with its prevalence and drug resistance, particularly in younger patients, the spotlight turns to new therapeutic targets like LY6G6D. Found within the MHC III gene cluster, LY6G6D plays a role in tumor cell growth, especially in cancer types that tend to metastasize and resist drugs. It's overexpressed in pMMR/MSS CRC, marking it as a promising target for novel treatments. KACTUS is at the forefront, offering high-quality recombinant LY6G6D proteins to accelerate the development of targeted therapeutics. Dive into the potential of LY6G6D 👉🏻 https://bit.ly/496n2wA #CancerTherapy #InnovativeResearch #KACTUS #ColorectalCancer #CRC #LY6G6D #TargetedTherapy #DrugDevelopment #Biotechnology

Source: Journal of pharmaceutical and biomedical analysis A study found distinct differences in the plasma molecular profiles of early-onset and late-onset colorectal cancer patients. Using metabolomics and lipidomics analyses, the study identified specific metabolites and lipids that were altered in the colorectal cancer group. The analysis also revealed that early-onset colorectal cancer patients had unique metabolomic and lipidomic profiles compared to late-onset patients. Gene expression data further supported these distinctions. The findings provide insights into the development mechanisms of early-onset colorectal cancer and potential plasma biomarkers for diagnosis.

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer:-

Happy to share our article published from our lab on our core research area ubiquitin proteasomal system (UPS) published in BBA Gene regulatory mechanism. The ubiquitin proteasomal system (UPS) represents a highly regulated protein degradation pathway essential for maintaining cellular homeostasis. This system plays a critical role in several cellular processes, which include DNA damage repair, cell cycle checkpoint control, and immune response regulation. Exploiting the UPS for cancer therapeutics offers promising avenues for developing innovative and effective treatment strategies, providing hope for improved patient outcomes in the fight against cancer. https://lnkd.in/dWBPW2SX

Oncotype DX Gene-Profiling Test Revolutionizes Breast Cancer Treatment Decision Making In a groundbreaking development for early-stage breast cancer patients, the gene profiling test Oncotype DX has emerged as a powerful tool to guide treatment decisions. This test, designed to estimate the risk of recurrence and predict the effectiveness of chemotherapy, is particularly valuable for patients characterized as estrogen receptor-positive (ER+) and human epidermal growth factor […] #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Dana-Farber, Brigham breakup could lead to a ripple effect for CGT clinical trials for cancer: Dana-Farber Cancer Institute announced on Sept. 14 that it is securing a new joint venture with Beth Israel Deaconess Medical Center, marking a breakup of its decadeslong adult cancer care partnership with Brigham and Women’s Hospital. The news shocked Brigham, which had been negotiating a partnership extension with Dana-Farber for the past 15 months, according to the Boston Globe. There are around 20 ongoing cell therapy clinical trials under the Dana-Farber Brigham Cancer Center, which comprises 12 treatment centers with experts from Dana-Farber and Brigham working together. Brigham also has its own gene and cell therapy institute and a lab dedicated to next-generation, genetically-modified CAR-T cell therapies for cancer. With the Dana-Farber contract set to end in 2028, concerns have been raised about the impact on current cell and gene therapy (CGT) studies and ones that are scheduled to start, due to the complex nature of the treatments involved. Jason Foster Manufacturing CGTs is a skill- and labor-intensive process. Ori Biotech CEO Jason Foster told Endpoints News that hospitals and research centers often work together to make them on-site for clinical trials, with highly skilled experts from the specialty centers playing a key role. UK-based Ori develops technologies that automates CGT manufacturing. At Dana-Farber Brigham Cancer Center’s cellular therapies program, cells are processed at an outside commercial facility or at the Connell and O’Reilly Families Cell Manipulation Core Facility. When such partnerships come to an end, “that kind of [specialist] knowledge loss is something that will impact both the trajectory of [CGT] trials, but also the time it takes to get these products to patients,” Foster added. These potential negative impacts on trials would only compound preexisting barriers to access to CGTs, including high costs and lengthy manufacturing processes. Estimates suggest that 25% of patients die while waiting for CAR-T treatments, according to ASCO Post. Lee Buckler Lee Buckler, senior vice president of advanced therapies at Blood Centers of America, told Endpoints in an email that collaboration between research institutes and healthcare providers was of significant — if not critical — value to the testing of CGTs. A Brigham spokesperson said that the hospital is one of the largest recipients of NIH funding and does not expect any changes to trials already under agreement, adding it would continue to be a leader in the CGT space. “We are also planning for a new, state of the art Brigham facility which will include the medical oncology specialty,” the spokesperson said. Dana-Farber did not respond to Endpoints before… #lucidquest #genetherapy #celltherapy